Abeona Therapeutics (NASDAQ:ABEO) Receives “Buy” Rating from HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 135.85% from the stock’s previous close.

Several other brokerages also recently weighed in on ABEO. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $6.36 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48. The stock’s 50 day simple moving average is $5.99 and its 200-day simple moving average is $5.17. The company has a market cap of $260.52 million, a PE ratio of -1.99 and a beta of 1.53. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.42). As a group, equities research analysts anticipate that Abeona Therapeutics will post -1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in Abeona Therapeutics in the 1st quarter valued at approximately $91,000. Western Standard LLC boosted its holdings in Abeona Therapeutics by 68.5% in the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock valued at $9,871,000 after acquiring an additional 553,377 shares during the last quarter. Rosalind Advisors Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter valued at $7,420,000. Bank of New York Mellon Corp raised its position in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 2,434 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares in the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.